News for Zymeworks Inc. (ZYME)

Six posters highlight continued progress across antibody-drug conjugate and T cell engager platforms Novel T cell engager ZW209 demonstrates durable activity i

VANCOUVER, British Columbia, April 21, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. ( ZYME), a clinical-stage biotechnology company developing a diverse pipeline o

VANCOUVER, British Columbia, April 17, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. ( ZYME), a clinical-stage biotechnology company developing a diverse pipeline o

**media[576922]**

VANCOUVER, British Columbia, March 26, 2025 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline…

**media[576525]**

On March 24, 2025, EcoR1 Capital, LLC (Trades, Portfolio), a prominent investment firm, made a strategic move by increasing its stake in Zymeworks Inc (ZYME). T

On March 19, 2025, EcoR1 Capital, LLC (Trades, Portfolio) executed a notable transaction by acquiring an additional 228,463 shares of Zymeworks Inc at a trade p

On March 13, 2025, EcoR1 Capital, LLC (Trades, Portfolio), a prominent investment firm, made a significant move by acquiring an additional 1,081,980 shares of Z

Zymeworks (ZYME) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Zymeworks Inc. (NASDAQ:ZYME) Q4 2024 Earnings Conference Call March 5, 2025 4:30 PM ETCompany ParticipantsShrinal Inamdar - Director, Investor...

Zymeworks (ZYME) delivered earnings and revenue surprises of 3.12% and 15.54%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

First-in-human global studies initiated for ZW191, an antibody-drug conjugate (ADC) engineered to target folate receptor-⍺ (FR⍺) and ZW171, a bispecific 2 + 1 T cel…

Zymeworks Inc (ZYME) is set to release its Q4 2024 earnings on Mar 5, 2025. The consensus estimate for Q4 2024 revenue is $45.20 million, and the earnings are e

**media[550677]**

VANCOUVER, British Columbia, Feb. 26, 2025 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME) a clinical-stage biotechnology company developing a diverse pipeline o…

VANCOUVER, British Columbia, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Zymeworks Inc. ( ZYME) a clinical-stage biotechnology company developing a diverse pipeline of

**media[549431]**

VANCOUVER, British Columbia, Feb. 25, 2025 (GLOBE NEWSWIRE) — Zymeworks Inc. (Nasdaq: ZYME), a clinical-stage biotechnology company developing a diverse pipeline …